Related Experiment Video
Updated: Jun 11, 2026
10:56
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Statins for children with familial hypercholesterolemia
Alpo Vuorio1, Jaana Kuoppala, Petri T Kovanen
1Mehilainen Airport Medical Center, Vantaa, Finland.
The Cochrane Database of Systematic Reviews
|July 9, 2010
Summary
Statins effectively lower LDL cholesterol in children with familial hypercholesterolemia. While short-term safety appears good, long-term effects require further investigation in pediatric patients.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pediatrics
Background:
- Familial hypercholesterolemia (FH) is a common inherited metabolic disorder affecting approximately 1 in 500 individuals worldwide.
- Early diagnosis in children is crucial, often based on elevated low-density lipoprotein cholesterol (LDL-C) levels or DNA analysis, as premature atherosclerosis and cardiovascular complications can occur.
- Traditional treatments like diet and anion exchange resins have limitations in efficacy and tolerability, necessitating alternative therapeutic strategies.
Purpose of the Study:
- To evaluate the effectiveness and safety of statin therapy in pediatric patients diagnosed with familial hypercholesterolemia.
- To synthesize evidence from randomized controlled trials assessing statins versus placebo or diet in children with FH.
Main Methods:
- A systematic search of relevant trials was conducted using the Group's Inborn Errors and Metabolism Trials Register and Medline.
- Eight randomized placebo-controlled trials, including 897 participants up to 18 years of age, were included in the analysis.
- Data on lipid levels, liver enzymes, creatine kinase, and clinical adverse events were extracted and analyzed.
Main Results:
- Statins significantly reduced mean low-density lipoprotein cholesterol (LDL-C) concentrations in children with familial hypercholesterolemia at all measured time points.
- No significant differences were observed in serum aspartate aminotransferase, alanine aminotransferase, or creatine kinase levels between statin and control groups.
- The incidence of myopathy and other clinical adverse events was similar in both treatment and placebo groups, suggesting short-term safety.
Conclusions:
- Statin therapy demonstrates efficacy in lowering LDL-C levels for children with familial hypercholesterolemia.
- While short-term safety appears favorable, the long-term safety profile of statins in this pediatric population remains unknown.
- Careful monitoring by pediatricians is recommended for children on statin therapy, and further long-term randomized controlled trials are warranted.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:18Lipids: Dietary Sources and Requirements
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...